OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Psychopharmacology is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Science, safety and education: Informing the psychedelic treatment of psychiatric disorders	218
The effects of the PDE4 inhibitor roflumilast on cognitive performance after a cerebrovascular accident: a double-blind randomized placebo-controlled trial with an open label extension (ROSTMEMA)	144
Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice	133
Circadian rhythmicity in prepulse inhibition of the acoustic startle response: A study of chronotype and time-of-day effects in young healthy adults	103
Effects of initial nicotine exposure on cognition and nicotine reinforcement among non-smoking young adults with and without attention deficit hyperactivity disorder	74
Award winning abstracts presented at the 15 ^th Annual International College of Mental Health Pharmacy (CMHP) Conference, Liverpool, UK, on 10	60
Deaths related to the use of diarylethylamines, with a focus on the United Kingdom: A systematic review and case series report	59
Off the RADAR; questions regarding the trial protocol of a randomised controlled trial of antipsychotic reduction and discontinuation	58
Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study	56
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study	54
Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study	53
Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat	53
Neurocognitive changes in lithium-treated older adult bipolar patients on antipsychotics	53
Psychedelics and the ‘inner healer’: Myth or mechanism?	52
Co-use of psychedelics with other substances: Findings from the global psychedelic survey	51
Preliminary evidence that serum interleukin-6 is a candidate biomarker of response to esketamine in treatment-resistant depression	50
The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies	47
Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment	47
Relationship between change in social evaluation learning and mood in early antidepressant treatment: A prospective cohort study in primary care	42
An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine	42
The effects of antenatal depression and SSRI exposure on children: A systematic review	40
A framework for assessment of adverse events occurring in psychedelic-assisted therapies	39
Dynamic excitatory-inhibitory differences in autistic and non-autistic adults: Evidence from a pharmacological challenge with arbaclofen	39
Psychedelic research – Going global	37
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy	37

Comparison of average time-to-relapse following ECT versus ketamine – A systematic review	36
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool	33
Associations between regular cannabis use and brain resting-state functional connectivity in adolescents and adults	33
The D1/D2-like receptor antagonist flupentixol and the D2-like receptor antagonist L-741626 decrease operant responding for nicotine and food and locomotor activity in male and female rats	33
Ketamine use in a large global sample: Characteristics, patterns of use and emergency medical treatment	32
Pharmaco-fUS in cognitive impairment: Lessons from a preclinical model	32
Mind the gap! Addressing unresolved aspects of abuse potential evaluation and scheduling of classic and novel psychedelic drugs	31
Serotonin release by parachloroamphetamine in rats with high and low sociability: High prefrontal release capacity in sociable females	31
Voluntary nicotine consumption and reward in a subset of diversity outbred founder strains	31